On November 18, 2023, the 17th China Brand Festival was grandly held in Yunqi Town, Hangzhou. On site, Mr. Wang Yong, the initiator and secretary-general of the China Brand Festival and chairman of the Brand Alliance, released the Top Brand 2023 Global Brand 500 ranking. It is reported that the selection scope of this list covers 37164 well-known enterprises in 47 countries around the world. A comprehensive evaluation of brand value is conducted around five dimensions: brand size, brand premium, brand internationalization, brand awareness, and brand core competitiveness. Xiuxiu Pharmaceutical Group Co., Ltd. was awarded the World Top 500 Brands honor for the first time with a valuation of 14.527 billion US dollars. As a leading private pharmaceutical enterprise in China's top 100 pharmaceutical industry for 12 consecutive years, it showcases the charm of Chinese pharmaceutical enterprises to the world.
Mr. Xiu Cheng, Vice President of Xiu Pharmaceutical Group, took the stage as a representative to receive the award.
As a large modern private pharmaceutical enterprise group, Xiuxiu Pharmaceutical Group has five well-known trademarks (Xiuxiu, Tongyao, Stasu, Weidanning, and Shuangxiao), forming a cluster development pattern of "15 sales platforms" and "33 production bases (including drugs, health products, and food)", mainly producing "Stasu", "Xiaomi Suppository", "Weidaning", "Yiqi Yangxue Oral Liquid" "Feining Granules" and 24 other dosage forms, over a thousand drugs, over a thousand health products and cosmetics, are popular nationwide and have the largest OTC market network in the country.
After 28 years of construction and development, Xiuxiu Pharmaceutical Group has owned 80 independent intellectual property products and more than 1000 patents. The group firmly believes in the cultural confidence that "traditional Chinese medicine is a treasure of the Chinese nation", is committed to inheriting and promoting the essence of traditional Chinese medicine, and deeply cultivates the high-precision and cutting-edge field of biopharmaceuticals, keeping up with international pharmaceutical cutting-edge technology, and producing special drugs that meet the actual needs of China's pharmaceutical market and patients. Among them, PEG based uric acid oxidase and PEG based follicle stimulating hormone are pioneering in China and will fill the domestic gap.
With strong capabilities in implementing the entire production, research, and sales chain, this revision of the Pharmaceutical Group not only ranks among the world's top 500 brands, but also has been awarded multiple honors such as the "Huapu Award" and "China's Top 500 Brands".
Since its official layout in the field of big health in 2001, the forward-looking strategic vision, diversified product types, and the advantages of base resources in more than ten cities across the country have helped to successfully transform the Pharmaceutical Group from a traditional pharmaceutical enterprise to a modern pharmaceutical enterprise that covers the entire industry chain of big health with professional development and two wings flying together. Practice the concept of "cultivating, cultivating, and revising" in the health industry, actively respond to the requirements of the Healthy China strategy, and transform from a focus on disease treatment to a focus on people's health.
In 2022, the revised pharmaceutical group achieved a revenue of 66.9 billion yuan and fully completed its annual production and operation tasks. Vice President Xiu Cheng of the group stated in an interview that Xiu Xiu Pharmaceutical will continue to adhere to the principle of "cultivating the original, benefiting the people", never forget the original intention, cure diseases, remember the mission, and ensure the health of the people at all times. We will produce "medicine of conscience, reliable and effective" to contribute to the protection of the health of the people.
